Adjuvant mRNA-4157 Plus Pembrolizumab Prolongs RFS versus Pembrolizumab Alone in Patients with Resected High-Risk Melanoma
Findings from KEYNOTE-942 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
Neoadjuvant Histotype-Tailored Treatment with Trabectedin Not Inferior to Standard Chemotherapy with Anthracycline Plus Ifosfamide in High-Grade Myxoid Liposarcoma
Results of the expanded cohort of a randomised study from Italian, Spanish, French, and Polish sarcoma groups
FDA Approves Belzutifan for Advanced Renal Cell Carcinoma
Evidence for efficacy is based on the results from the LITESPARK-005 study
Proof of Concept for the Safety and Immunogenicity of Lymph Node Targeting KRAS Mutation Specific Amphiphile Vaccine and Promising Signal of Clinical Activity
Findings from the AMPLIFY-201 study
EMA Recommends Granting a Marketing Authorisation for Pomalidomide Viatris
It is a generic of Imnovid, which has been authorised in the EU since 2013
The First Report from the Cancer Programme of the 100,000 Genomes Project
The 100,000 Genomes Project establishes the infrastructure and resources for linking genomic and longitudinal clinical life course data
Durable Activity of Repotrectinib in Patients with ROS1 Fusion–Positive NSCLC Regardless of Previous Treatment with a ROS1 TKI
Findings from the TRIDENT-1 study
EMA Recommends Granting a Marketing Authorisation for Generic Eribulin
Mevlyq is a generic of Halaven, which has been authorised in the EU since 2011
Neoadjuvant Atezolizumab Plus Chemotherapy Is Safe and Has Promising Activity in Patients with Gastric and Gastro-oesophageal Junction Adenocarcinoma
Findings from the PANDA study
Potential Value of ctDNA NGS-based Analysis of Imatinib Resistant Secondary KIT Mutations to Select Second-Line Treatment for Patients with Advanced GIST
Findings from the exploratory analysis of the INTRIGUE study
Adding Pembrolizumab to Chemotherapy with or without Bevacizumab Improves Overall Survival Across Subgroups of Patients with Persistent, Recurrent, or Metastatic Cervical Cancer
Findings from subgroup analyses of the KEYNOTE-826 study
FDA Approves Enfortumab Vedotin-ejfv with Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer
Evidence for efficacy is based on the results from the EV-302/KN-A39 study